Desmopressin (DDAVP)

Summary

Desmopressin is a modified vasopressin (a lab-made version of the body's water-saving hormone) that acts almost only on kidney V2 receptors, so it concentrates urine for 8 to 12 hours without raising blood pressure, and at high doses it releases the stored clotting proteins factor VIII and von Willebrand factor. It has been FDA approved since 1978 for central diabetes insipidus (the brain makes too little of this hormone, causing heavy urination and thirst) and is also approved for mild hemophilia A and von Willebrand disease type 1, primary nocturnal enuresis (bedwetting; tablets), and nocturia due to nocturnal polyuria, waking to urinate because the body makes too much urine at night (Nocdurna, Noctiva). Its main risk is hyponatremia (dangerously low blood sodium), which prompted a 2007 FDA alert and the withdrawal of the nasal spray for bedwetting, and low dose nocturia products carry a boxed warning, FDA's most serious label warning.

What is Desmopressin?

Desmopressin is a synthetic nonapeptide analog of vasopressin, selective for the V2 receptor. It is also known as DDAVP, Desmopressin acetate, 1-deamino-8-D-arginine vasopressin, Nocdurna, Noctiva, Stimate, Minirin.

How does it work?

Desmopressin binds V2 receptors on renal collecting duct cells, raising cyclic AMP and moving aquaporin-2 water channels to the cell surface, so water is reabsorbed and urine concentrates. The deamination and D-arginine substitution remove most V1 (vasoconstrictor) activity and extend duration. At doses roughly 10 times higher than antidiuretic doses, V2 stimulation of endothelial cells releases factor VIII and von Willebrand factor, raising plasma levels 3 to 5 fold within an hour.

FDA-approved uses of Desmopressin

Yes, since 1978. Current DDAVP labels cover central diabetes insipidus (too little of the body's water-saving hormone, causing heavy urination and thirst; tablets, nasal spray, and injection), primary nocturnal enuresis (bedwetting; tablets only), and, for the injection, maintaining hemostasis (stopping bleeding) in hemophilia A and type 1 von Willebrand disease when factor VIII activity is above 5%. Low dose products for nocturia due to nocturnal polyuria (waking to urinate because of excess nighttime urine; Nocdurna and Noctiva) were also approved. It is prescription only and available as generics. [5] [6] [8] [9]

What does the evidence say about Desmopressin?

Extensive randomized and controlled evidence across indications. For bleeding disorders, 20 years of studies reviewed by Mannucci 1997 show a 3 to 5 fold rise in factor VIII and von Willebrand factor in responders with mild hemophilia A and type 1 von Willebrand disease. For nocturia, a 2014 systematic review found desmopressin reduced nocturnal voids by roughly half a void per night more than placebo and prolonged the first undisturbed sleep period, with hyponatremia as the limiting harm. Weatherall 2004 pooled older adult studies and found clinically significant hyponatremia in about 7.6% of those treated for nocturia. Enuresis and diabetes insipidus efficacy rest on the original label trials.

Human evidence

Mannucci 1997: review of two decades of clinical use showing desmopressin 0.3 ug/kg raises factor VIII and von Willebrand factor about 3 to 5 fold in mild hemophilia A and type 1 von Willebrand disease, allowing many minor procedures without plasma products. Ebell 2014: systematic review of randomized trials of desmopressin for adult nocturia; desmopressin reduced nocturnal voids modestly versus placebo (on the order of 0.5 to 1 fewer voids per night) and increased the time to first void, with hyponatremia more frequent in older patients and at higher doses. Weatherall 2004: meta-analysis of desmopressin for nocturia in older adults, pooled incidence of hyponatremia 7.6%. Juul 2017: low doses (25 ug women, 50 ug men) with serum sodium monitoring reduced clinically significant hyponatremia, the basis of the sex specific dosing in Nocdurna.

Animal evidence

Animal pharmacology established V2 selectivity, minimal pressor effect, and the antidiuretic dose response; toxicology found no carcinogenicity signal. Human data supersede animal work for this drug.

Key studies

Conditions studied

Is Desmopressin legal in the United States?

FDA and compounding status

FDA approved as DDAVP injection in 1978 for central diabetes insipidus, with nasal and tablet forms following for diabetes insipidus, hemophilia A, von Willebrand disease type 1, and primary nocturnal enuresis. In December 2007 FDA alerted prescribers to severe hyponatremia and removed the enuresis indication from intranasal products. Noctiva (2017) and Nocdurna (2018) were approved for nocturia due to nocturnal polyuria with a boxed warning for hyponatremia. Generic tablets, nasal sprays, and injections are widely available, so compounding is limited to patient specific needs.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

1. Sep 21, 2026WADA

   WADA publishes the 2027 Prohibited List

   WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

   Source: WADA 2027 Prohibited List
2. Jan 1, 2026WADA

   WADA 2026 Prohibited List takes effect

   The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

   Source: WADA Prohibited List
3. Jan 1, 2025WADA

   WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

   The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 (TB-500), and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

   Source: WADA Prohibited List

Full tracker for Desmopressin or the category-wide tracker.

Desmopressin dose on the FDA label

Doses below are quoted from the FDA label for its approved uses, plus the doses used in the pivotal trials where noted. The prescriber sets the dose; PeptideAgent does not recommend doses or protocols.

FDA labels (DailyMed). DDAVP tablets: central diabetes insipidus, start at 0.05 mg twice daily and adjust; most patients use 0.1 to 0.8 mg a day in divided doses, within a 0.1 to 1.2 mg daily range; primary nocturnal enuresis (age 6 and older), 0.2 mg at bedtime, titrated up to 0.6 mg, with fluids limited from 1 hour before the dose until the next morning. Desmopressin nasal spray, central diabetes insipidus: 10 to 40 mcg a day in adults as one dose or divided into two or three, and 10 up to 30 mcg a day in children 4 and older; it is not indicated for bedwetting. DDAVP injection: diabetes insipidus, 2 to 4 mcg a day subcutaneously or intravenously in one or two doses; hemophilia A and type 1 von Willebrand disease with factor VIII above 5%, 0.3 mcg/kg (maximum 20 mcg) by intravenous infusion. Serum sodium is checked because every form can cause hyponatremia.

Routes reported

What are the side effects and interactions of Desmopressin?

Side effects

Interactions

Contraindications

How do people access Desmopressin legally?

Typical cost: Generic desmopressin tablets cost roughly 20 to 80 USD per month at cash prices; generic nasal spray roughly 50 to 200 USD per bottle. Nocdurna and Noctiva brand products list at several hundred USD per month. Insurance generally covers desmopressin for approved indications.

• Rules by state
• Verified provider directory

Frequently asked questions

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

• BPC-157 nasal spray: what is and is not known about intranasal use

  No published study has given BPC-157 as a nasal spray to animals or people. What the one nose-related rat study tested, what a nasal peptide must prove, and its legal status.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.